Oncotarget cover image

Oncotarget

UGDH in Clinical Oncology and Cancer Biology

Oct 4, 2023
In this podcast, researcher Meghan J. Price discusses UDP-glucose dehydrogenase (UGDH) and its role in tumor progression. The review paper explores UGDH as a molecular indicator of tumor progression, its involvement in cancer signaling pathways, and potential therapeutic targets and prognostication markers.
02:10

Episode guests

Podcast summary created with Snipd AI

Quick takeaways

  • UDP-glucose dehydrogenase (UGDH) can serve as a molecular indicator of tumor progression in multiple cancer types.
  • Inhibiting UGDH and its downstream products could be a potential therapeutic strategy for cancer treatment.

Deep dives

UGDH as a molecular indicator of tumor progression

A new review paper published in Enco Targets Vol. 14 discusses the role of UDP-glucose dehydrogenase (UGDH) as a molecular indicator of tumor progression in multiple cancer types. The researchers from various institutions classify UGDH as an enzyme involved in key canonical cancer signaling pathways and highlight its potential as a prognostication marker in oncology. They also identify methods to inhibit UGDH and its downstream products, positioning it as a therapeutic target in cancer biology.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode